GLPwatch
Papers (10409)
Page 109 of 174, ranked by citation count.
- South Asian consensus guideline: Use of GLP-1 receptor agonists during Ramadan: Update 2016 Revised Guidelines on the use of GLP-1A in Ramadan.
- Optoacoustic Imaging of Glucagon-like Peptide-1 Receptor with a Near-Infrared Exendin-4 Analog.
- Unravelling the mechanisms of a protein refolding process based on the association of detergents and co-solvents.
- Efficacy and safety of lixisenatide as add-on therapy to basal insulin in older adults with type 2 diabetes in the GetGoal-O Study.
- Discovery of lixisenatide analogues as long-acting hypoglycemic agents using novel peptide half-life extension technology based on mycophenolic acid.
- Protective effect of liraglutide on experimental testicular ischaemia reperfusion in rats.
- Quality of Life, Glycemic Control, Safety and Tolerability Associated with Liraglutide or Insulin Initiation in Patients with Type 2 Diabetes in Germany: Results from the Prospective, Non-interventional LIBERTY Study.
- A Conserved Hydrophobic Moiety and Helix-Helix Interactions Drive the Self-Assembly of the Incretin Analog Exendin-4.
- Efficacy and safety of once-weekly semaglutide 2.4 mg for weight management in participants from China: A prespecified analysis of the STEP 7 randomized clinical trial.
- Liraglutide in Acute Minor Ischemic Stroke or High-Risk Transient Ischemic Attack With Type 2 Diabetes: The LAMP Randomized Clinical Trial.
- Role of endogenous GLP-1 and its agonists in osteopenia and osteoporosis: but we little know until tried.
- Impact of Insulin Sensitivity and β-Cell Function Over Time on Glycemic Outcomes in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE): Differential Treatment Effects of Dual Therapy.
- GLP-1/GIP dual agonist tirzepatide alleviates mice model of Parkinson's disease by promoting mitochondrial homeostasis.
- Predictive factors of body weight loss in patients with type 2 diabetes treated with GLP-1 receptor agonists: a 52-week prospective real-life study.
- Liraglutide alleviates high-fat diet-induced kidney injury in mice by regulating the CaMKKβ/AMPK pathway.
- Analysing the effects of National Centralised Drug Procurement and Price Negotiation Policies on novel hypoglycaemic drug usage and costs in Shanghai, China: an interrupted time series analysis.
- <i>KCNQ1</i> variant rs163184 is a potential biomarker of glycemic response to exenatide.
- Cutaneous hypersensitivity reaction to dulaglutide: A case report of an allergic reaction.
- Glimepiride Compared to Liraglutide Increases Plasma Levels of miR-206, miR-182-5p, and miR-766-3p in Type 2 Diabetes Mellitus: A Randomized Controlled Trial.
- Achieving postprandial glucose control with lixisenatide improves glycemic control in patients with type 2 diabetes on basal insulin: a post-hoc analysis of pooled data.
- Renal outcomes with the newer antidiabetes drugs: the era before and after CREDENCE.
- Harnessing GLP-1 Receptor Agonists for Obesity Treatment: Prospects and Obstacles on the Horizon.
- Quantitative Comparison of Glucagon-Like Peptide-1 Receptor Agonists on Weight Loss in Adults: A Systematic Review and Model-Based Meta-Analysis.
- Compounded glucagon-like peptide-1 receptor agonists for weight loss: the direct-to-consumer market in Colorado.
- Rational design and biological evaluation of gemfibrozil modified Xenopus GLP-1 derivatives as long-acting hypoglycemic agents.
- Phase 3 efficacy and safety trial of proposed liraglutide biosimilar for reduction of glycosylated hemoglobin (HbA1c) in patients with Type 2 diabetes mellitus.
- Glucagon-like Peptide-1 Receptor Agonists in the Management of Diabetic Retinopathy.
- Cost-Effectiveness Analysis of Exenatide versus GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus.
- GLP-1 receptor agonists for the treatment of obstructive sleep apnea and obesity.
- Exendin-4 Attenuates Hepatic Steatosis by Promoting the Autophagy-Lysosomal Pathway.
- Exenatide-induced granulomatous panniculitis associated with poly(d,l-lactide-co-glycolide).
- The Hypoglycemic and Hypocholesterolemic Activity of <i>Dioscorea deltoidea</i>, <i>Tribulus terrestris</i> and <i>Panax japonicus</i> Cell Culture Biomass in Rats with High-Fat Diet-Induced Obesity.
- A case for screening real-world data for collateral drug benefits: Glucagon-like peptide 1 receptor agonists and bile acid diarrhea.
- Safety and Effectiveness of Dulaglutide in the Treatment of Type 2 Diabetes Mellitus: A Korean Real-World Post-Marketing Study.
- Long-term tolerance and efficacy of adjunctive exenatide therapy on glycaemic control and bodyweight in type 2 diabetes: a retrospective study from a specialist diabetes outpatient clinic.
- Lack of preservation of insulin gene expression by a glucagon-like peptide 1 agonist or a dipeptidyl peptidase 4 inhibitor in an in vivo model of glucolipotoxicity.
- Frailty and Effects of Semaglutide in Obesity-Related HFpEF: Findings From the STEP-HFpEF Program.
- New insight on the role of liraglutide in alleviating dexamethasone-induced pancreatic cytotoxicity via improving redox status, autophagy flux, and PI3K/Akt/Nrf2 signaling.
- Corrigendum: GLP-1RAs caused gastrointestinal adverse reactions of drug withdrawal: a system review and network meta-analysis.
- Effects of Dulaglutide and Insulin Glargine on Estimated Glomerular Filtration Rate in a Real-world Setting.
- Effect of tirzepatide on blood pressure levels in overweight/obese individuals without diabetes.
- [Effects of liraglutide on the expression of local renin-angiotensin system, transforming growth factor-β1 and collagen type III in pulmonary tissue of diabetic rats].
- Novel Anti-glycemic Drugs and Reduction of Cardiovascular Risk in Diabetes: Expectations Realized, Promises Unmet.
- [<sup>68</sup> Ga]Ga-DOTATATE PET/CT versus [<sup>68</sup> Ga]Ga-Exendin-4 PET/CT in the evaluation of metastatic insulinoma.
- Treatment Patterns and Persistence With GLP-1 RA Treatments Among Patients With Type 2 Diabetes in France: A Retrospective Cohort Analysis.
- Smoke or fire? Acute pancreatitis and the liraglutide trials.
- Clinical outcomes of concomitant therapy of exenatide twice daily and basal insulin in patients with type 2 diabetes mellitus: a retrospective database analysis in the United States.
- Oral Semaglutide: The First-available Noninjectable Glucagon-like Peptide 1 Receptor Agonist.
- Cardiovascular outcomes and safety of semaglutide in non-overweight populations with type 2 diabetes: a comparison with dipeptidyl peptidase 4 inhibitors.
- Oral semaglutide for the treatment of obesity: a retrospective real-world study.
- Advances in Clinical Cardiology 2016: A Summary of the Key Clinical Trials.
- Impact of GLP-1 Receptor Agonist Use in Patients With Steatotic Liver Disease and Type 2 Diabetes: A Retrospective Cohort Study.
- Liraglutide pharmacotherapy reduces body weight and improves glycaemic control in juvenile obese/hyperglycaemic male and female rats.
- Influence and significance of intervening diabetes microRNA expression profile of NOD mice with exendin-4.
- Exenatide improves cardiovascular risk factors in obese patients with type 2 diabetes mellitus: a prospective study
- iGlarLixi reduces residual hyperglycemia in Japanese patients with type 2 diabetes uncontrolled on basal insulin: A post-hoc analysis of the LixiLan JP-L trial.
- Dulaglutide and Glomerular Hyperfiltration, Proteinuria, and Albuminuria in Youth With Type 2 Diabetes: Post Hoc Analysis of the AWARD-PEDS Study.
- Dulaglutide Shows Sustained Reduction in Glycosylated Hemoglobin Values: 2-Year US Real-world Study Results.
- 'This Is My Decision': A Qualitative Study of Individuals' Perspectives on Use of Semaglutide for Weight Loss.
- The improved health utility of once-weekly subcutaneous semaglutide 2.4 mg compared with placebo in the STEP 1-4 obesity trials.